Eton Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Mar 14, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 14, 2024
ETON$64.35+14.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Operations
(In thousands, except per share amounts)
| For the years ended | |||
|---|---|---|---|
| December 31, | December 31, | December 31, | |
| 2023 | 2022 | 2021 | |
| Revenues: | |||
| Licensing revenue | $5,500 | $10,000 | $19,000 |
| Product sales and royalties, net | 26,142 | 11,251 | 2,832 |
| Total net revenues | 31,642 | 21,251 | 21,832 |
| Cost of Sales: | |||
| Licensing revenue | 1,000 | 1,640 | 1,500 |
| Product sales and royalties | 9,581 | 5,293 | 1,327 |
| Total cost of sales | 10,581 | 6,933 | 2,827 |
| Gross profit | 21,061 | 14,318 | 19,005 |
| Operating expenses: | |||
| Research and development | 3,322 | 3,996 | 6,235 |
| General and administrative | 18,931 | 18,582 | 14,265 |
| Total operating expenses | 22,253 | 22,578 | 20,500 |
| Loss from operations | (1,192) | (8,260) | (1,495) |
| Other income (expense): | |||
| Interest and other income (expense), net | 503 | (761) | (1,006) |
| Gain on PPP loan forgiveness | — | — | 365 |
| Gain on equipment sale | — | — | 181 |
| Loss before income tax expense | (689) | (9,021) | (1,955) |
| Income tax expense | 247 | — | — |
| Net loss | $(936) | $(9,021) | $(1,955) |
| Net loss per share, basic and diluted | $(0.04) | $(0.36) | $(0.08) |
| Weighted average number of common shares outstanding, basic and diluted | 25,645 | 25,146 | 25,207 |
Eton Pharmaceuticals, Inc.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.